SkinBioTherapeutics (LON:SBTX) Issues Earnings Results

SkinBioTherapeutics (LON:SBTX – Get Free Report) released its quarterly earnings data on Monday. The company reported GBX (0.31) earnings per share (EPS) for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative net margin of 15.01% and a negative return on equity of 10.01%. The company had revenue of GBX 217 million for the quarter.

SkinBioTherapeutics Trading Up 0.5%

Shares of SBTX stock opened at GBX 9.75 on Monday. The company has a debt-to-equity ratio of 10.55, a quick ratio of 10.01 and a current ratio of 4.84. SkinBioTherapeutics has a 1 year low of GBX 5 and a 1 year high of GBX 27.50. The stock has a fifty day moving average of GBX 9.73 and a two-hundred day moving average of GBX 12.80. The firm has a market capitalization of £25.27 million, a PE ratio of -31.45 and a beta of 0.47.

Get SkinBioTherapeutics alerts:

About SkinBioTherapeutics

(Get Free Report)

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.

Further Reading

• Five stocks we like better than SkinBioTherapeutics
• The Market May Be Missing What’s Changing at BigBear AI
• These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
• 3 Stocks Under $20 to Buy Before a Broader Market Rally
• Petco Faces Tough Competition, But Momentum Is Building

Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.